Randomized Controlled Trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's Syndrome.

Bowman, SJ; Everett, CC; O'Dwyer, JL; Emery, P; Pitzalis, C; Ng, WF; Pease, CT; Price, EJ; Sutcliffe, N; St Gendi, N; +13 more... Hall, FC; Ruddock, SP; Fernandez, C; Reynolds, C; Hulme, CT; Davies, KA; Edwards, CJ; Lanyon, PC; Moots, RJ; Roussou, E; Giles, IP; Sharples, LD; Bombardieri, M; (2017) Randomized Controlled Trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's Syndrome. Arthritis & rheumatology (Hoboken, NJ). ISSN 2326-5191 DOI: https://doi.org/10.1002/art.40093

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1002/art.40093

Abstract

Share

Download

Filename: Randomized Controlled Trial of Rituximab and costeffectiveness_GREEN AAM.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar